Scroll Back to Top
June 28, 2024

Biomarkers Europe 2024

Join us at Biomarkers Europe 2024
Basel, Switzerland


September 30 - October 1, 2024
Booth 29
 

Day one - September 30, 2024 | 9:20 AM

June 20, 2024

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer

In this study,  we utilized real-world comprehensive genomic and immune profiling (CGIP) data derived from testing many patients with NSCLC (>8,000) during their standard care to look for differences in genomic alterations and immune activity in younger versus older patient tumors. We found important differences in younger patient tumors including higher frequency of genomic alterations in key NSCLC driver genes and less immune activity overall, especially when looking at male patient tumors. Taken together, our results show the value of CGIP for informing clinical treatment of younger patients with NSCLC and provides support for broader coverage of CGIP for younger patients.

Molecular Tumor Board: 77-year-old female with metastatic breast cancer with PIK3CA H1047R mutation and 83-year-old female with metastatic breast cancer with AKT1 L52R mutation

Dr. Marcela Mazo Canola, Assistant Professor of Medicine, Breast Medical Oncology at UT Health San Antonio Mays Cancer Center joined our Oncology Medical Affairs Directors, Kyle Strickland and Heidi Ko to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. Two cases of metastatic hormone receptor-positive, HER2-negative breast cancer with PIK3CA and AKT1 alterations were discussed.